Navigation Links
Valeant Announces Pricing of Senior Notes
Date:11/18/2010

gram).

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.About Valeant Pharmaceuticals International, Inc.Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.

Caution Regarding Forward-Looking Information and "Safe Harbor" StatementThis press release may contain forward-looking statements, including, but not limited to, our financing plans. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties relating to the proposed merger, as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... a new market research report is available in its ... Market Report: 2010 Edition http://www.reportlinker.com/p0304775/Global-In-Vitro-Diagnostics-IVD-Market-Report-2010-Edition.html ... been experiencing rapid growth, in spite of the economic ... prevention of diseases among the people, which is expected ...
... today announced that industry veteran Glenn Kazo has assumed the ... capacities with Prolong since 2007. He succeeds Prolong founder Dr. ... have known Glenn for more than thirty years," said Dr. ... "I feel he is one of the greatest strategic minds ...
Cached Medicine Technology:Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 2Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 3Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 4Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 5Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President 2
(Date:12/22/2014)... (PRWEB) December 22, 2014 Sagacious Consultants, ... add a subscription option to their ad hoc report ... writing services. Customers can sign up for an annual ... hours each month at a deeply discounted hourly rate. ... and each has a progressively discounted rate. Subscription hours ...
(Date:12/22/2014)... Dec. 19, 2014 (HealthDay News) -- U.S. and state ... caramel apples that has killed at least four people ... should not eat any commercially produced, prepackaged caramel apples ... Disease Control and Prevention said in a news release. ... people had been infected with the outbreak strains of ...
(Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... Christmas is days away, and last minute ... easy solution that will please: the Sublime Gift Card ... from $25 up to $350," says Kathy Heshelow, founder of ... a wide array of skin care products and Skin Brushes." ... dates. , Gift delivery past shipping deadlines, or those ...
Breaking Medicine News(10 mins):Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... Calif., July 8 ChemoCentryx, Inc. today announced ... Officer, will give a keynote lecture at The 9th World ... "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and ... given on Thursday, July 9, 2009 at 9:00 am local ...
... Save Roughly $3,000 A Year By Switching From Expensive Brand ... Hyperactivity Disorder (ADHD) , , YONKERS, N.Y., July 8 ... Buy Drugs report, parents should be skeptical if their doctors ... of attention deficit hyperactivity disorder (ADHD). Free samples can ...
... Switzerland, 8 July 2009 - The International Diabetes Federation ... World Heart Federation (WHF) called today on the UN,s ... to avert the fastest growing threat by non-communicable diseases ... cardiovascular disease, diabetes, cancer and chronic respiratory disease, cause ...
... BETHEL, Conn., July 8 MedClean Technologies, Inc. (OTC Bulletin ... to exchange all of the Company,s existing Common Stock Purchase ... August 29, 2008 ("Existing Warrants") for newly issued Common Stock ... per share, exercisable for one-half the original number of shares ...
... July 8 Universal Health Services, Inc. (NYSE: UHS ... its Board of Directors. He becomes the eighth member of the ... of Hayground Cove Capital Partners LLC, in New York, NY, a ... that, Mr. Silvers was a Vice President at Fortress Investment Group ...
... , , , HARRISBURG, Pa., July 8 ... his office, the departments of Health and Education, and the ... H1N1 Influenza Preparedness Summit in Maryland on July 9. , ... information that will be used in Pennsylvania,s ongoing efforts to ...
Cached Medicine News:Health News:ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan 2Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 2Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 3Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 4Health News:The next health tsunami: Noncommunicable diseases 2Health News:MedClean Technologies Announces Results of Private Exchange Offer 2Health News:Rendell Administration Officials to Participate in National Flu Summit 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: